H.C. Wainwright & Co., LLC

Join us for the next HCW@Home on Tuesday, April 22 at 10am EST, featuring NRx Pharmaceuticals, Inc. Vernon Bernardino, HCW Research Analyst, will host an in-depth conversation with Dr. Jonathan Javitt, Founder, Chairman & Chief Scientific Officer, and Matthew Duffy, Chief Business Officer of NRx. They'll discuss the company’s therapeutic pipeline targeting central nervous system (CNS) disorders, and spotlight HOPE Therapeutics—an NRx subsidiary advancing a premier network of interventional psychiatry clinics dedicated to delivering breakthrough treatments for depression and post-traumatic stress disorder (PTSD).   To register, visit https://lnkd.in/eXqKNqeC

Yesterday, our Vice Chairman and Head of M&A and Strategic Advisory Services, Michael Meyers, had the privilege of participating in a thought-provoking fireside chat keynote at the #CMO360Summit in Boston. The conversation delved into the evolving biotech financial landscape, offering valuable insights and a deeper understanding of the current trends shaping the industry. It was a productive session that fostered meaningful dialogue and knowledge sharing among industry leaders, further solidifying the future of biotech innovation and strategic growth. A huge thank you to Chief Medical Officer 360º for hosting such a dynamic and impactful event!

We are pleased to kick off our 2025 Emerging Ideas in Biopharma call series led by Research Analyst Douglas Tsao. The series will consist of weekly calls, beginning April and continuing through June, highlighting biopharma companies with differentiated strategies. The first call will feature Steve Mahoney, CEO of Viridian Therapeutics, Inc., and is scheduled for Tuesday April 8th at 10am EST. To register for the series, please visit https://lnkd.in/eyr_8Cy7. 

Michael Meyers, our Vice Chairman and Head of M&A and Strategic Advisory Services, will be featured in the Biotech Investment Banking Keynote: Fireside Discussion at the 13th Annual CMO360 Summit in Boston next Tuesday, April 8th. Moderated by Ed Tucker, Chief Medical Officer at Jasper Therapeutics, the session will explore the biotech financial landscape, with Michael sharing his insights on how investors and strategic partners evaluate companies and examining the key trends and factors driving capital markets, M&A, and strategic transactions.

Join us tomorrow, April 2nd, for the 2nd Annual Artificial Intelligence-Based Drug Discovery & Development Conference. This event will feature in-depth presentations, fireside chats, and expert panels focused on the applications of AI in accelerating drug discovery, optimizing development processes, and advancing AI-designed drug pipelines. Don’t miss this opportunity to hear from leading industry professionals at the forefront of AI innovation in pharmaceuticals. For more information on the conference, please visit https://lnkd.in/d4aACadD.

H.C. Wainwright & Co. is proud to announce our #1 ranking for the 40th consecutive quarter in PlacementTracker’s Market League Tables by transaction volume. In the first quarter of 2025, the firm completed 37 transactions, reinforcing our position as the top firm in the space, and has successfully executed 76 transactions totaling $25.4B year-to-date. We extend our sincerest gratitude to our clients and remain committed to navigating dynamic markets and adapting to the ever-changing needs of our clients while delivering exceptional service. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions.

TuHURA Biosciences, Inc. will be featured in the HCW@Home session on Thursday, April 3rd at 11am EST. Research Analyst Robert Burns will be joined by TuHURA’s Chief Executive Officer, James Bianco, MD, to discuss the company’s pipeline, strategic outlook, upcoming advancements, and more. To register, please visit https://lnkd.in/eeC4J9En.

As we wrap up an insightful first quarter, we’re proud to reflect on our HCW@Home Virtual Fireside Chat Series. In each session, company management shared valuable perspectives, with our research analysts leading the engaging discussions on key trends and strategies.   In case you missed any of the sessions, all the Q1 replays are now available for on-demand viewing via our HCW Media Room at https://lnkd.in/ejUWwwN. After registration, scroll down to the section titled "H.C. Wainwright @ Homes 1Q2025". Thank you to the companies that joined us: Altimmune, Inc., Arqit, Bit Digital | NASDAQ: BTBT, BitFuFu, BTCS Inc. (Nasdaq: BTCS), CalciMedica, Candel Therapeutics, Elicio Therapeutics, Evaxion Biotech A/S, and Gyre Therapeutics.

We are pleased to have served as Lead Manager for Humacyte’s $50 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

The 15th session of our Biotech Breakthroughs series will feature a virtual fireside chat with leading oncology experts Professor Martine Piccart and Dr. Alexander Eggermont. The discussion will focus on oncolytic immunotherapies, with a particular emphasis on ongoing clinical trials in metastatic breast cancer (MBC) and metastatic pancreatic ductal adenocarcinoma (mPDAC).   Register for the Biotech Breakthrough series at https://lnkd.in/epEUdRzw